Navigation Links
AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1,Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV,Irradiated Skin Cells

Clinical Data Presented at the Society for Investigative Dermatology

FREEPORT, N.Y., May 16, 2007 /PRNewswire-FirstCall/ -- AGI Dermatics today announced new clinical research that the 8-oxo-guanine DNA glycosylase (OGG1) encapsulated in liposomes enhances DNA repair and reduces MMP-1 and TNF-alpha in UV irradiated skin cells. The data was presented at the 68th Annual Meeting of the Society for Investigative Dermatology, May 9 - 12, in Los Angeles, CA.

"Our clinical study suggests that OGGI liposomes enhance DNA repair in skin cells," said Daniel Yarosh, PhD, President, AGI Dermatics. "This is particularly exciting when we consider that existing data shows that 8-oxo- guanine causes the most significant damage to mitochondrial DNA, which manifests as nearly all signs of premature aging."

The study examined the question of, if by damaging DNA with reactive oxygen species (ROS) would there be an increase of either/both matrix metalloproteinase-1 (MMP-1) and tumor necrosis factor, two factors known to play roles in photoaging. The formation of 8-oxo-G is induced by ROS from UVA irradiation, cigarette smoke, environmental stressors, endogenous enzymatic peroxidation reactions and normal mitochondrial metabolism. Those mentioned account for nearly all of the symptoms of premature skin aging. Long-term exposure consequences include photodamage, fine lines and wrinkles.

Natural cellular repair of the oxidative damage entails complete removal of 8-oxo-G from DNA via the enzyme OGGI. For the test, OOGI encapsulated in liposomes showed that the delivery of this enzyme into fibroblasts increases the rate of repair of 8-oxo-G, and reduces mitochondrial toxicity and analyzed mRNA content and protein secretion of MMP-1 and TNF-alpha, with real-time RT- PCR and ELISA.

Normal human dermal fibroblasts (NHDF) were irradiated with solar- stimulating (ss) UV (UVA340 bulb) to induce MMP-1. Following irra diation, cells were treated with 1ug/mL OGG1 liposomes for up to 48 hours. The study then looked at the results of "repair by damaging" the DNA. The treatment of ssUV stimulated NHEK results in an increased TNF-alpha mRNA expression after 24 hours and TNF secretion after 48 hours. Both ssUV-induced TNF- mRNA and secreted protein were reduced by 50% following OGG1 liposome treatment.

In conclusion, these results indicate that treatment of dermal fibroblasts and epidermal keratinocytes with OGG1 liposomes enhance DNA repair, leads to a reduction in the expression and/or secretion of stress responses proteins such as ssUV-induced MMP-1 and ssUV-induced TNF-a mRNA.

AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Remergent DNA Repair Formula and Antioxidant Refoliator both contain Roxomes, liposomes encapsulating OGG1, which protect the cells genetic material from ROS.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. www.agiderm.com

CONTACT: Courtney McGeever, +1-212-317-1462, for AGI Dermatics

Web site: http://www.agiderm.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The global travel vaccines market to ... The report covers the present scenario and the growth prospects ... market size, the report considers the revenue generated from the sales ...
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016  The global ... of 8.8% during the forecast period of 2016 to ... billion by 2021 from USD 18.21 billion in 2016. ... surgeries, rising incidences of sports related injuries and spinal ... and rising need of effective blood loss management. ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company is a ... As a means of expanding capabilities Flottman has added a G&K Vijuk TTM ... professional inserts (PIs) and patient package inserts (PPIs) that will marry with all ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide ... Columbia as an education tool in the war against teen drug abuse. NCADD ...
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a device ... The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is also ... a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is a ...
(Date:12/9/2016)... Fort Lee, NJ (PRWEB) , ... December 09, ... ... the 2016 Founders Ball at The Pierre Hotel in New York, NY, on ... 700 friends, benefactors, dignitaries and physicians attended the annual event, which raised over ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
Breaking Medicine News(10 mins):